This review uncovers the role of the NFE2L2/AP-1 interactome in drug resistance and diagnostics, suggesting new therapeutic approaches.
In humans the NFE2L2/AP-1 pathway controls more than 5% of the protein-coding genes. This pathway is responsible for cellular reactions towards ROS xenobiotics highly reactive substances of various nature drug resistance and a plethora of other intracellular intercellular and microenvironment functions. The great diversity of the pathway functions is astonishing and raises questions of how the pathway operates to provide the cell with specific enough reactions. The present review focuses on current knowledge in the field. Today the pathway functioning is already used in developing novel pharmaceutics and diagnostics approaches in therapy follow-up. Filling the existing blanc spots of the NFE2L2/AP-1 interactome would significantly advance the related fields and open new horizons in medical technologies.
No takes yet. Share an insight, caveat, or question.
ZOLOTUKHIN et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: